Outsourcing in clinical development among global biopharma companies by size 2023
According to a survey conducted in 2023, 38 percent of biopharma executives whose companies are outsourcing stated that the full-service model is their current outsourcing model of clinical development work. The full-service model was more common among small and mid-sized companies (40 percent) than among large companies (35 percent). This statistic describes the distribution of outsourcing models in clinical development among biopharmaceutical companies worldwide, by size of the company.